Obsidian Therapeutics(OBX)
Focus: Obsidian Therapeutics is a public-stage biotechnology company focused on cell and gene therapies, primarily in oncology, operating from Cambridge, MA with 51-200 employees. The company is early-stage with a single Phase 1/2 program in clinical development.
Profile data last refreshed 12h ago · AI intelligence enriched 3w ago
Funding Stage
PUBLIC
Employees
51-200
Open Jobs
8+1 this month
Stable — net +1 jobs in 30d
7 added, 6 removed. Backfill posture.
Should You Work at Obsidian Therapeutics?
AI assessmentBest suited for early-career scientists and clinical professionals seeking formative experience in cell/gene therapy development within a public, focused-pipeline biotech; higher risk-tolerance required.
Why Work Here
- Join a public biotech focused on high-impact cell and gene therapies in oncology, a rapidly growing modality with significant unmet medical need.
Data completeness
4/9 — Basic
Company HealthSolid
Pipeline
Early-stage
1 total
LOE Risk
Protected
No near-term cliffs
Hiring
Stable
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Pipeline & Clinical Trials
OBX-115
Tumor SkinClinical Trials (1)
NCT06060613Safety and Efficacy of OBX-115 in Advanced Solid Tumors
Phase 1/2Help build intelligence for Obsidian Therapeutics
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.